株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

中国の糖尿病市場の分析:患者数、有病率、経口抗糖尿病剤、インスリン、診断薬

China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics

発行 IMARC Services Pvt. Ltd. 商品コード 345918
出版日 ページ情報 英文 51 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.95円で換算しております。
Back to Top
中国の糖尿病市場の分析:患者数、有病率、経口抗糖尿病剤、インスリン、診断薬 China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics
出版日: 2017年02月15日 ページ情報: 英文 51 Pages
概要

中国は世界最大の糖尿病患者人口を抱えており、また近年では成人の間で発症者数が急速に増加しています。約30年前には、糖尿病患者は成人人口の1%未満でしたが、現在では約12%にまで拡大しています。その要因として、急速な経済成長や都市化、食生活の変化 (脂肪・白米の消費量増加)、認知度の低さ、貧弱な医療インフラ、座り仕事中心の生活 (運動量の低下) の他、中国人が全般的に西洋人よりも糖尿病に罹りやすい体質であることなどが挙げられます。政府や医療関係者の緊急対応が求められている一方で、こうした状況は、糖尿病の治療薬・診断薬メーカーにとっては巨大な市場機会の出現とも言えるでしょう。

当レポートでは、中国国内の糖尿病治療薬・診断薬の市場について分析し、有病者数の推移・予測や構造 (年齢・性別など)、市場への主な影響要因、治療薬・診断薬の市場規模と今後の見通し、今後の市場機会などについて調査・推計しております。

第1章 分析手法

第2章 エグゼクティブ・サマリー

第3章 糖尿病の概要

  • 糖尿病とは何か?
  • 糖尿病の診断と治療
    • 診断法
    • 治療法
  • 糖尿病の併発症

第4章 中国の糖尿病市場の主な促進要因

第5章 中国国内の糖尿病の疫学

  • 糖尿病の患者人口と有病率
  • 糖尿病の患者人口と有病率:種類別 (1型・2型)
  • 糖尿病の患者人口と有病率:地域別
  • 糖尿病の患者人口と有病率:男女別
  • 糖尿病の患者人口と有病率:年齢層別
  • 糖尿病の診断率・薬剤治療率

第6章 中国の糖尿病市場

  • これまでの市場動向 (過去8年間分)
  • 部門別の詳細動向 (過去8年間分)
  • 中国の経口抗糖尿病剤の市場
    • これまでの市場動向 (過去8年間分)
    • クラス別の市場区分 (過去8年間分)
    • 主要企業の市場シェア
    • 市場の将来展望 (今後6年間分)
  • 中国のインスリン市場
  • 市場の将来展望 (今後6年間分)

第7章 中国の糖尿病診断薬市場

  • これまでの市場動向 (過去8年間分)
  • 市場の内訳
  • 主要企業
  • 市場の将来展望 (今後6年間分)

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: SRP00116HB

China currently has the highest number of diabetics in the world. The disease has presently reached epidemic proportions in the adult population. Around three decades ago, less than one percent of the Chinese adult population had diabetes. These levels, however, have increased to around 12 percent - making it the diabetes capital of the world.

The rise of diabetes in China can be attributed to a number of factors. Driven by a strong economic growth over the past few decades, the Chinese population has become richer, fatter and less mobile. Apart from urbanisation and sedentary lifestyles, Chinese people are also genetically more vulnerable to diabetes compared to Europeans and many other population groups. Other factors such as poor awareness of health issues, high consumption of white rice, poor healthcare infrastructure, etc. have also driven the prevalence of the disease.

China's diabetes statistics may ring alarm bells for the government and healthcare authorities, for drug and diagnostic manufacturers, however, it represents a goldmine. Fuelled by a continuous increase in healthcare expenditures, the market for diabetes drugs and diagnostics is expanding robustly in the country. This is creating lucrative opportunities for global healthcare companies at a time when growth rates in the more developed markets have declined.

IMARC's new report "China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics" provides an analytical and statistical insight into the Chinese diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in China. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Chinese diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the China diabetes market in any form.

What we have achieved in this report:

Comprehensive situation analysis of the Chinese diabetes epidemiology and its dynamics:

Focus of the Analysis:

  • Historical, current and future prevalence of diabetes in China
  • Historical, current and future prevalence of type-1 and type-2 diabetes in China
  • Historical, current and future prevalence of diabetes in the urban and rural regions in China
  • Historical, current and future prevalence of diabetes among males and females in China
  • Historical, current and future prevalence of diabetes among various age groups in China
  • Historical, current and future diagnosis rates for diabetes in China
  • Historical, current and future drug treatment rates for diabetes in China

Comprehensive situation analysis of the Chinese Oral Antidiabetics market and its dynamics:

Focus of the Analysis:

  • Performance of the Oral Antidiabetics market in China
  • Performance of key classes
  • Performance of key players
  • Market outlook

Comprehensive situation analysis of the Chinese Insulin market and its dynamics:

Focus of the Analysis:

  • Performance of the Insulin market in China
  • Performance of key classes
  • Performance of key players
  • Market outlook

Comprehensive situation analysis of the Chinese diabetes diagnostics market and its dynamics:

Focus of the Analysis:

  • Performance of the diabetes diagnostics market in China
  • Market Segmentation
  • Key players
  • Market outlook

Table of Contents

1 Preface

2 Research Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Diabetes Disease Overview

  • 5.1 What is Diabetes?
  • 5.2 Diabetes Diagnosis and Treatment
    • 5.2.1 Diagnosis
    • 5.2.2 Treatment
  • 5.3 Diabetes Complications

6 China Diabetes Epidemiology

  • 6.1 Diabetes Population and Prevalence Rates
  • 6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
  • 6.3 Population and Prevalence Rates by Region
  • 6.4 Population and Prevalence Rates by Gender
  • 6.5 Population and Prevalence Rates by Age Group

7 China Diabetes Market

  • 7.1 Market Overview
  • 7.2 Market Performance
  • 7.3 Market Forecast
  • 7.4 SWOT Analysis
    • 7.4.1 Strengths
    • 7.4.2 Weaknesses
    • 7.4.3 Opportunities
    • 7.4.4 Threats
  • 7.5 Value Chain Analysis
  • 7.6 Porter's Five Forces Analysis
    • 7.6.1 Overview
    • 7.6.2 Bargaining Power of Buyers
    • 7.6.3 Bargaining Power of Suppliers
    • 7.6.4 Degree of Competition
    • 7.6.5 Threat of New Entrants
    • 7.6.6 Threat of Substitutes
  • 7.7 Market Breakup by Segment
    • 7.7.1 China Oral Antidiabetics Market
      • 7.7.1.1 Historical Market Trends
      • 7.7.1.2 Market Breakup by Class
      • 7.7.1.3 Market Shares of Key Players
      • 7.7.1.4 Market Forecast
    • 7.7.2 China Insulin Market
      • 7.7.2.1 Historical Market Trends
      • 7.7.2.2 Market Breakup by Class
      • 7.7.2.3 Market Shares of Key Players
      • 7.7.2.4 Market Forecast
  • 7.8 Competitive Landscape
    • 7.8.1 Competitive Structure
    • 7.8.2 Profiles of Key Players

List of Figures

  • Figure 1: The Impact of Diabetes in the Human Body
  • Figure 2: Diabetes Complications
  • Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2016 & 2035
  • Figure 4: China: Overweight & Obese Population* (in Million), 2010, 2016 & 2022
  • Figure 5: Body Mass Index and Relative risk of Type-2 Diabetes
  • Figure 6: China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+), (in %)
  • Figure 7: China: Diabetes Prevalence By Age Groups, (in %)
  • Figure 8: China: Total Number of Diabetes Patients* (in 000), 2009-2016
  • Figure 9: China: Total Number of Diabetes Patients* Forecast (in 000), 2017-2022
  • Figure 10: China (Type1 & Type2): Total Number of Diabetes Patients* (in 000), 2009- 2016
  • Figure 11: China (Type1 & Type2): Total Number of Diabetes Patients* (in 000), 2017-2022
  • Figure 12: China (Urban & Rural): Total Number of Diabetes Patients* (in 000), 2009 -2022
  • Figure 13: China (Urban & Rural): Total Number of Diabetes Patients* (in 000), 2017 - 2022
  • Figure 14: China (Male & Female): Total Number of Diabetes Patients* (in 000), 2009 - 2016
  • Figure 15: China (Male & Female): Total Number of Diabetes Patients* (in 000), 2017 - 2022
  • Figure 16: China: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2009 - 2016
  • Figure 17: China: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2017 - 2022
  • Figure 18: China: Diabetes Drug Industry Overview
  • Figure 19: China: Diabetes Drug Market (in Million US$), 2009 - 2016
  • Figure 20: China: Diabetes Drug Market Forecast (in Million US$), 2017 - 2022
  • Figure 21: China: Diabetes Drug Market: SWOT Analysis
  • Figure 22: China: Diabetes Drug Market: Value Chain Analysis
  • Figure 23: China: Diabetes Drug Market: Porters Five Forces Analysis
  • Figure 24: China: Diabetes Drugs Market: Breakup of Insulin and Oral Antidiabetics (in %), 2009 - 2016
  • Figure 25: China: Diabetes Drugs Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2017 - 2022
  • Figure 26: China: Oral Antidiabetics Market: (in Million US$), 2009 - 2016
  • Figure 27: China: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2009 & 2016
  • Figure 28: China: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
  • Figure 29: China: Oral Antidiabetics Market: (in Million US$), 2017 - 2022
  • Figure 30: China: Insulin Market, (in Million US$), 2009 - 2016
  • Figure 31: China: Breakup of Insulin Market by Class (in %)
  • Figure 32: China: Insulin Market: Sales Share of Key Players (in %)
  • Figure 33: China: Insulin Market Forecast (in Million US$), 2017 - 2022

List of Tables

  • Table 1: Diagnosis of Diabetes
  • Table 2: Global: Diabetes Population Breakup by Country (in 000's), 2016 & 2035
  • Table 3: China: Overweight &Obesity Statistics, 2010, 2016 & 2022
  • Table 4: China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+), (in Million)
  • Table 5: China: Total Prevalence & Number of Diabetes Patients*, 2009, 2016 & 2022
  • Table 6: China (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
  • Table 7: China (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
  • Table 8: China (Male & Female): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
  • Table 9: China: Total Prevalence & Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (In Millions), 2009, 2016 & 2022
  • Table 10: China: Diabetes Drug Market: Competitive Structure
Back to Top